+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Protective anti-tumor immunity in a murine neuroblastoma model is induced by gene therapy with single chain interleukin-12, but not interleukin-2



Protective anti-tumor immunity in a murine neuroblastoma model is induced by gene therapy with single chain interleukin-12, but not interleukin-2



Proceedings of the American Association for Cancer Research Annual Meeting (41): 195




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 035577075

Download citation: RISBibTeXText


Related references

Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma. Proceedings Of The National Academy Of Sciences Of The United States Of America. 95(5): 2475-2480, Ch 3, 1998

Interferon-gamma inducible protein 10 is required for CTL-mediated systemic tumor-protective immunity induced by single chain interleukin-12 gene therapy. Proceedings of the American Association for Cancer Research Annual Meeting (41): 290, 2000

Anti-tumor immunity induced by Interleukin-12 gene therapy in a metastatic model of breast cancer is mediated by natural killer cells. Breast Cancer Research & Treatment 60(2): 129-134, 2000

Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis: Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis and Rheumatism 40(2): 249-260, 1997

Induced immunity by expression of interleukin-2 or GM-CSF gene in murine neuroblastoma cells can generate antitumor response to established tumors. Cancer Gene Therapy 6(5): 395-401, 1999

Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma. Cancer Research 61(16): 6178-6184, 2001

Immunogene therapy with interleukin 12 , B7-1 and Flt3 ligand in a murine myeloma model IL-12 and B7-1 expressing cells confer protective immunity. Blood 90(10 Suppl. 1 Part 1): 358A-359A, 1997

Protective immunity is induced in murine colon carcinoma cells by the expression of interleukin-12 or interleukin-18, which activate type 1 helper T cells. Cancer Gene Therapy 7(2): 247-254, 2000

A recombinant anti-ganglioside GD2 antibody interleukin-2 fusion protein amplifies the efficiency of gene therapy with a single chain interleukin-12 fusion protein. Proceedings of the American Association for Cancer Research Annual Meeting 39: 654, 1998

Pathogenic role of interleukin-6 in the development of sepsis. Part II: Significance of anti-interleukin-6 and anti-soluble interleukin-6 receptor-alpha antibodies in a standardized murine contact burn model. Critical Care Medicine 31(5): 1495-1501, 2003

Construction of vectors expressing bioactive single-chain murine interleukin-12 for gene therapy. FASEB Journal 14(6): A1131, 2000

Construction of vectors expressing bioactive heterodimeric and single-chain murine interleukin-12 for gene therapy. Human Gene Therapy 9(4): 457-465, 1998

Anti-interleukin-10R1 monoclonal antibody in combination with bacillus Calmette--Guérin is protective against bladder cancer metastasis in a murine orthotopic tumour model and demonstrates systemic specific anti-tumour immunity. Clinical and Experimental Immunology 177(1): 261-268, 2014

Effects of interleukin-4 or interleukin-10 gene therapy on trinitrobenzenesulfonic acid-induced murine colitis. Bmc Gastroenterology 13: 165, 2013

Cytokine gene therapy with interleukin-2-transduced fibroblasts: effects of IL-2 dose on anti-tumor immunity. Human Gene Therapy 6(5): 591-601, 1995